You are correct. At 1.5 I was nearly at break even so I was/ am incredibly angry at the events around the GBA announcement. Had the timing been managed it would be 2-3 cents now post CR. The sector, the disease, lack of other treatment and even the tech seem good. And if they turn it around it could do great for shareholders. Lange is doing the right things he just doesn’t have the momentum yet. Trying both to fund studies and sell is proving hard. Once they can break even from European business they can start on USA. Not the preferred pathway but they have no choice. Usually companies can switch from research to selling. Also I’ve underestimated how much of a football its been for some players. Essentially I guess I still think it’s v undervalued. I’m still of the opinion it would be worth 5x current ev in a company sale. If both pancosil and Tripp turn up good results sentiment could change significantly. But then I might be deluded. It only matters what brokers and funds think.
OSL Price at posting:
0.7¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)